Nurix Therapeutics, Inc. - Common stock (NRIX) Covered Calls

Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation for cancer and autoimmune diseases. It utilizes its DEL-AI platform to develop small molecules that modulate E3 ligases. Nurix aims to create transformative therapies by harnessing the body’s natural protein disposal system.

You can sell covered calls on Nurix Therapeutics, Inc. - Common stock to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for NRIX (prices last updated Tue 4:16 PM ET):

Nurix Therapeutics, Inc. - Common stock (NRIX) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
16.02 +0.64 15.05 16.90 894K - 1.6
Covered Calls For Nurix Therapeutics, Inc. - Common stock (NRIX)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Mar 20 16 0.40 16.50 -3.0% -43.8%
Apr 17 16 0.80 16.10 -0.6% -4.1%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Nurix Therapeutics, Inc. (NASDAQ: NRIX), based in San Francisco, California, is a clinical-stage biopharmaceutical leader pioneering a new class of drugs known as targeted protein degraders. The company’s approach centers on the ubiquitin-proteasome system, the cell’s natural machinery for recycling proteins. By designing small molecules that bridge disease-causing proteins with E3 ligases, Nurix triggers the selective destruction of those targets. This "catalytic" mechanism allows for deeper and more durable therapeutic effects than traditional inhibitors, potentially addressing a vast spectrum of hard-to-treat cancers and inflammatory conditions.

Core Business and Products

  1. Bexobrutideg (NX-5948): This is a potent, orally bioavailable, and brain-penetrant BTK degrader. It is currently in pivotal Phase 2/3 trials for relapsed or refractory chronic lymphocytic leukemia (CLL). Its ability to cross the blood-brain barrier makes it a unique candidate for treating central nervous system lymphomas.
  2. Zelebrudomide (NX-2127): A novel bifunctional degrader targeting both BTK and the neosubstrates Ikaros and Aiolos. It is being evaluated for B-cell malignancies, offering a dual mechanism that may overcome resistance encountered by current standard-of-care therapies.
  3. NX-1607 (CBL-B Inhibitor): This first-in-class oral small molecule targets CBL-B, an E3 ligase that negatively regulates T cell activation. By inhibiting this "brake" on the immune system, NX-1607 acts as an immuno-oncology agent to enhance the body's natural anti-tumor response.
  4. DEL-AI Platform: Nurix’s proprietary discovery engine combines DNA-encoded libraries (DEL) with artificial intelligence. This platform allows for the rapid screening of billions of compounds to identify highly specific binders for challenging E3 ligase targets.

Competitive Landscape

Nurix operates in the rapidly evolving targeted protein degradation (TPD) sector, where it competes with other platform-based biotech firms. Its most direct peers include Kymera Therapeutics and Arvinas, Inc., both of which have advanced degrader programs in the clinic. In the oncology and BTK-inhibitor space, it faces competition from established players like Eli Lilly and AstraZeneca. In the broader immunology market, it overlaps with Regeneron and Sanofi. Nurix differentiates itself through its deep expertise in E3 ligase liganding and its strong strategic partnerships with Gilead, Pfizer, and Sanofi.

Strategic Outlook and Innovation

Nurix’s 2026 strategy is defined by its transition into a late-stage clinical company, with a primary focus on the global registration of bexobrutideg. The company is executing its DAYBreak™ pivotal program, which includes Phase 2 and confirmatory Phase 3 studies designed to support accelerated approval in CLL. To fuel this expansion, Nurix maintains a robust financial position with over $650 million in cash and investments. This capital provides a clear runway to achieve several key clinical catalysts while continuing to advance its internal and partnered pipelines in autoimmune and inflammatory diseases.

Innovation at Nurix is centered on expanding its "Degrader-Antibody Conjugates" (DACs) and leveraging its AI-driven discovery engine. The company is exploring how to combine the cell-targeting specificity of antibodies with the potent catalytic activity of protein degraders to create next-generation precision medicines. Furthermore, the 2026 roadmap includes a major push into autoimmune indications, supported by a new oral tablet formulation of its lead candidates. By integrating machine learning with structural biology, Nurix seeks to maintain its edge in the TPD revolution, delivering safer and more durable responses for patients with high unmet medical needs.